The combination of diagnostics and therapeutics into a single "theragnostic" agent is a key breakthrough. This approach allows for better patient stratification and offers new hope for cancers like pancreatic ductal adenocarcinoma (PDAC), which have dismal survival rates.
The most effective CRO partnerships transcend a simple client-vendor dynamic. Success hinges on viewing the CRO as an integrated part of the research team, fostering close collaboration in study design and maintaining open, continuous communication.
There is no inherent conflict between speed and quality. High-quality studies prevent costly setbacks and generate reliable data, ultimately accelerating research programs. A low-quality study is what truly delays timelines by producing unusable or misleading results.
Unlike cell-line derived (CDX) models, PDX models are grown directly from patient samples without a culture phase. This preserves the original tumor's heterogeneity, leading to more clinically relevant and predictive data in preclinical radiopharmaceutical studies.